SS-31, also known as Elamipretide, MTP-131, or Bendavia, is a synthetic tetrapeptide compound developed for its potential therapeutic effects on mitochondrial function. It is composed of the amino acids D-arginine, dimethyltyrosine, lysine, and phenylalanine, forming a small, water-soluble peptide. The compound was designed to target and penetrate mitochondria, with synthesis methods focusing on enhancing its stability and bioavailability. Researchers have primarily investigated SS-31 in the context of mitochondrial dysfunction, which is implicated in a variety of age-related diseases and conditions. Studies have shown that SS-31 can improve mitochondrial function, reduce oxidative stress, and enhance cellular energy production, leading to potential benefits in conditions such as heart failure, kidney disease, and neurodegenerative disorders. The mechanism of action of SS-31 involves its interaction with cardiolipin, a phospholipid found in the inner mitochondrial membrane. By binding to cardiolipin, SS-31 stabilizes mitochondrial membranes, reduces the production of reactive oxygen species, and enhances ATP synthesis. This action helps to preserve mitochondrial function and protect cells from damage. Pharmacokinetic studies of SS-31 indicate that it has a relatively short half-life, with rapid distribution and clearance from the body. The compound is stable in its lyophilized form and shows good solubility in aqueous solutions, although its oral bioavailability is poor. Current research on SS-31 is focused on its therapeutic potential in clinical trials for various conditions, but it has not yet received regulatory approval as a medicinal product. Its status remains investigational, with ongoing studies to further elucidate its efficacy and safety profile.